

6-2018-4687 | Novel Chimeric System for Targeted Killing of Lymphocytic Cancer Cells
[Galski- Lorberboum Haya](#), HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology

Background

Considerable efforts have been invested in recent years in developing new, effective, yet less toxic drugs for targeted cancer therapy. Currently, this diverse group of drugs includes monoclonal antibodies, immunomodulators, proteasome inhibitors, tyrosine kinase inhibitors, and deacetylation agents.

Another approach to treating malignancies is the use of chimeric proteins.

Chimeric proteins, designed and constructed by gene fusion techniques, comprise both the cell targeting and the "active" moieties.

We now propose human pro-apoptotic proteins as new "active" domains of chimeric proteins to induce death of target cancer cells.

Patent Status

Contact for more information:



Keren-Or Amar
VP, Business Development, Healthcare

Yissum Research Development Company of the Hebrew University of Jerusalem

Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem
P.O. Box 39135, Jerusalem 91390 Israel
Telephone: 972-2-658-6688, Fax: 972-2-658-6689